SPRC ▲ +1.5% - SciSparc Ltd. $SPRC - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations SciSparc's subsidiary NeuroThera announced an expanded U.S. patent portfolio covering combinations of LSD, ketamine, and ibogaine developed through a collaboration with Clearmind, driving investor interest in the company's psychedelic drug development strategy. The 1.5% gain reflects positive sentiment around the strengthened intellectual property position in the emerging therapeutic psychedelics space. 23-SEP-2026 08:35 AM ET